ViiV, GSK gamble a surprise $130M chip in a high-stakes HIV playoff with Gilead
GlaxoSmithKline $GSK hasn’t had much to boast about over the last couple of years when it comes to new drug development. But ViiV — the HIV specialist which it controls a majority stake in — has proven to be a notable exception to that rule.
Today, ViiV continued to live up to its star billing inside GSK circles, noting that it filed twin applications at the FDA and the EMA for a combination of dolutegravir (Tivicay) and rilpivirine (J&J’s Edurant), which it plans to market as the world’s first two-drug maintenance therapy for keeping a lid on the lethal virus.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.